Let’s take this gentleman’s argument at face value that anyone can throw money at rockets and get something like Starship, Falcon or Dragon.
Perhaps he can explain to everyone how SpaceX is able to catch giant starships from orbit with chopsticks and deliver 85% of all Earth payload to orbit with Falcon, while Blue Origin, which started before SpaceX and was funded by the immensely wealthy Jeff Bezos, is not yet able to launch reliably?
Also, why is it that Boeing and Lockheed received several times what SpaceX did from the government for development of their rockets and spacecraft, but the Boeing capsule is still not operational and ULA delivers less than 5% of SpaceX payload to orbit?
I am genuinely curious about these questions.
Ocugen CEO @drsmusunuri joined @BBC Correspondent @JamesTGallagher at Cell & Gene Leaders Live to discuss our modifier gene therapy platform and its potential to address vision loss across a broader patient population.
#GeneTherapy #Biotech $OCGN
Ivan retweeted
$OCGN is targeting some of the biggest markets in biotech, with remarkable efficacy, a exceptional safety profile, hundreds of genetic mutations addressed with a single therapy, markets with little to no effective treatment options, a platform set to keep expanding with back to back pivotal results and commercialization right around the corner.
The markets are what they are, the numbers are what they are. Hell, I was breaking down these drugs numbers years ago showcasing the trillion dollar market potential you’re now seeing presented on the company’s slides.
My point is, if you’re buying this stock today, you’re buying what is clearly going to become one of the largest and most profitable biotech companies in history, before everyone else realizes it.
If you’ve ever wondered what it would’ve been like to buy into one of the giants of an industry at the ground floor, right before the steady rise to market leaders, well, you’re looking at one of those opportunities right now. It’s beyond obvious. 🍻
$ocgn Most will see “Phase 3 for GA in 2026” and shrug. The ones who know GA, the therapy and this market understand the gravity of what was just announced.
Dr. Jay Chhablan the Vice Chair of Clinical Trials at the University of Pittsburgh Medical Center Vision Institute just said the 6 month OCU410 data already looks superior to the FDA approved drugs when he compared them side by side.
Retail needs to understand why this sets OCU410 up as one of the most valuable medicines ever lined up to hit the market.
Why I’m saying that
OCU400 family keeps winning. OCU400 for IRDs, OCU410ST for Stargardt, and OCU410 for GA have shown consistent 100% efficacy signals with 100% safety to date. FDA’s recent CGT flexibility on self controlled designs external controls and registry follow up is also built for this platform and means a very fast path to market than anyone expects.
So why would OCU410 likely be the world’s most valuable drug and why has big pharma paid billions for early phase GA assets?
Because the numbers are staggering.
👇🍻💸🏦
$OCGN
Disruptive. What a fitting word. Brilliant conference @drsmusunuri . Congratulations to you and team Ocugen!
Today, at the @Stifel 2026 Healthcare Conference, Ocugen CEO @drsmusunuri highlighted our novel modifier #genetherapy platform and three Phase 3 investigational assets in NYC. #Biotech
Watch the replay: bit.ly/4zdvc2f
$OCGN
Today, at the @Stifel 2026 Healthcare Conference, Ocugen CEO @drsmusunuri highlighted our novel modifier #genetherapy platform and three Phase 3 investigational assets in NYC. #Biotech
Watch the replay: bit.ly/4zdvc2f
$OCGN
🚨 BREAKING: The FCC accepts SpaceX's application to acquire nationwide 800 MHz spectrum
Verizon, AT&T and T-Mobile all told SpaceX "NO" when it asked to use their networks. SpaceX is building its own:
This deal with Grain Management secures 546 paired licenses covering ~100% of the U.S. population, on 800 MHz low band that penetrates straight through walls and already works with almost every smartphone.
Once it closes, SpaceX will hold up to 89 MHz of spectrum in every market it touches.
Elon Musk: "This is the last critical piece of the spectrum puzzle needed for SpaceX to provide complete phone coverage in America."
ITS HAPPENING
Ivan retweeted
$OCGN once again expanded its global reach while retaining a significant share of future profits. 50% of gross profits plus royalties. The company is set up to collect checks in the mail to the tune of billions yearly. 🍻
Ivan retweeted
Our partnership with Celairis Therapeutics marks our third strategic regional agreement for OCU400 and another important step in advancing our global access strategy. We remain focused on bringing our potential one-time gene therapy closer to patients around the world.
Ocugen is expanding the potential reach of #OCU400 for #retinitispigmentosa through an exclusive licensing agreement with Celairis Therapeutics for #commercialization across Australia, New Zealand, and ASEAN markets with an estimated 725M+ people, following potential U.S. approval. $OCGN
🔗bit.ly/3Vk1ue6
Ivan retweeted
Charlie was murdered in the middle of a debate with people who hate him while wearing a shirt that said "freedom." He died defending Chappelle's right to be offensive. And Chappelle thanks him by reveling in his death.
But as offensive as that is, none of us who knew and loved Charlie want Chappelle to suffer the same fate. We don't want Chappelle dead, and we wouldn't "feel better" if someone murdered him. That's not how we respond to speech that offends us because we're not bloodthirsty lunatics.
If you're laughing about Charlie's murder, or feeling good about Charlie's murder, you're acting within your rights. You're free to be sadistic. But that's exactly what you are. Your soul is sick. The only thing I wish for you is that you'd come to realize it — before it's too late — and beg for God's forgiveness.
Ivan retweeted
Replying to @ThePatriotTea
I screenshot this on purpose. The trap was set, the bait was taken. This time, the bait has a tracker. Shit is about to go down
True
After DOGE, Elon came to a conclusion most people missed.
He tried to reform the state from the inside. He failed. And he said it plainly: the government can't fix its own deficit. Nobody in power actually wants to cut. The machine protects itself.
So he drew the only logical conclusion. If the state can't be reformed, there are only two ways this ends.
Either global bankruptcy. Debt keeps compounding, interest payments eat the budget, and the system collapses under its own weight.
Or robots. AI and robotics grow the economy so fast that the debt becomes manageable, and abundance makes the old fights over scarcity irrelevant.
Here's the part almost nobody sees.
For two centuries, capitalism has had a marketing problem. Its gains are real but slow and invisible. 2% growth a year doesn't feel like anything. Your life gets better over 30 years and you never connect it to the system that did it. Meanwhile, the left's promises feel immediate and concrete: a check, a subsidy, a benefit. That's why the left wins on promises even when it can't deliver them. Capitalism produces the wealth, socialism takes the credit.
Robots break that asymmetry.
When productivity doubles in a few years instead of a few decades, people will see it. Things get cheaper, services get better, opportunities appear, in real time. For the first time in history, people will connect capitalism and their rising standard of living directly, almost instantly. The causal chain becomes visible.
And that changes everything politically.
So there are two scenarios.
Scenario one: we stay in the current inertia. No breakthrough, or a breakthrough we regulate to death. The debt wins. Living standards stagnate, then fall. A frustrated electorate turns to whoever promises the most, and that pushes toward a hard collectivist left. But collectivism fails, as it always does. And when it fails, the most organized, most disciplined collectivist force left standing isn't the old left. It's radical Islamism. Bankruptcy, then communism, then something worse.
Scenario two: robots win. Abundance arrives, and it arrives visibly. The link between free enterprise and prosperity becomes obvious to everyone. And this is the key point: it becomes obvious to everyone, including the minorities the left was counting on. Because their long-term incentive is the same as everyone else's. A kid in the suburbs gains infinitely more from a booming, abundant West than from a bankrupt state handing out promises it can't keep. Abundance is the most powerful integration machine ever built.
That's the Western renaissance.
The West doesn't need to win the culture war by arguing. It needs to win it by delivering. And for the first time, it has the technology to deliver fast enough for people to notice.
The race isn't left vs right anymore. It's robots vs bankruptcy.
Ivan retweeted
A milestone-driven third quarter for Ocugen as we continue advancing our pipeline, expanding our global reach, and preparing for potential commercialization. Proud of our team's continued progress and execution.
Today, CEO @drsmusunuri highlighted 3Q 2026 milestones:
• #OCU400: Provisional Approval and Priority Designation in the Bahamas and a licensing agreement in MENA + topline results from Phase 3 anticipated in 1Q 2027
• #OCU410: Phase 3 dosing initiated
• $84.6M in cash and cash equivalents; runway into 2028
Read: bit.ly/4iW3gLo
#QuarterlyUpdate $OCGN
Today, CEO @drsmusunuri highlighted 3Q 2026 milestones:
• #OCU400: Provisional Approval and Priority Designation in the Bahamas and a licensing agreement in MENA + topline results from Phase 3 anticipated in 1Q 2027
• #OCU410: Phase 3 dosing initiated
• $84.6M in cash and cash equivalents; runway into 2028
Read: bit.ly/4iW3gLo
#QuarterlyUpdate $OCGN
Ivan retweeted
$OCGN We’re talking about a pre Rev biotech that’s just months away from pivotal results. If you bought this stock but didn’t buy it for the catalyst, then what exactly were you buying it for, and why have you held this whole time?
Over the past year, the stock has ranged from $0.70-$2.50. If SP was your whole reason for buying, could’ve sold at $2.50. But if you actually bet on the products, then buck up buttercup. The current price range is about to be completely irrelevant.
Examples of pre rev biotechs heading into pivotal Phase 3 results:
1. ABVX (2025)
Bled 72% before Phase 3 results.
Then went from $4.77 to $148.83.
2. CPXX (2016)
Bled 64% before Phase 3 results.
Then went from $1.12 to $30.36.
3. CELC (2025)
Bled 66% before Phase 3 results.
Then went from $7.58 to $120.32.
If this platform validates itself the way the evidence increasingly suggests it will, we’re talking about a market opportunity that makes all those examples look insignificant. 🍻
🤖 Made with AI
Ivan retweeted
“The man who can walk away from what he desires for the sake of what he must become is a man no one can own.”
— Epictetus
Ocugen is taking part in two key industry events this November!
CEO @drsmusunuri will participate in the Stifel 2026 Healthcare Conference and Cell & Gene Leaders Live 2026. Read more: bit.ly/4ss67Pm
#HealthcareInnovation #GeneTherapy $OCGN
What if one gene could influence the activity of many? 🧬
Ocugen’s novel modifier gene therapy uses master regulator genes to influence multiple gene networks, with the potential to address major blindness diseases.
Watch our video to learn more. #GeneTherapy $OCGN
Ivan retweeted
Thank you to CMS Administrator @DrOzCMS, Deputy Administrator @AbeSutton, and the @CMSInnovates Center team for expanding the Cell and Gene Therapy Access Model beyond sickle cell disease. An important step toward greater patient access and continued biotech innovation.
At Cleveland Clinic today, CMS Innovation Center Director Abe Sutton, @DrOzCMS, and @FDA_KyleD announced that CMS will invite manufacturers of other cell and gene therapies to apply to the CGT Access Model. Learn more: go.cms.gov/CGT



















































